Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 8 de 8
Filter
1.
J Assist Reprod Genet ; 39(3): 765-775, 2022 Mar.
Article in English | MEDLINE | ID: mdl-35142968

ABSTRACT

PURPOSE: To evaluate the expressions of caspase-3 and cytochrome c and heat shock protein 70 (Hsp70) in granulosa cells (GCs) from women with normal ovarian reserve (NOR) and diminished ovarian reserve (DOR) undergoing intracytoplasmic sperm injection (ICSI). METHODS: GCs were collected from 117 infertile women during oocyte retrieval. Patients were classified into four groups as follows: DOR-COC score of 0, DOR-COC score of I, NOR-COC score of 0, and NOR-COC score of I. The caspase-3, cytochrome c, and Hsp70 analyses were performed immunohistochemically in GCs. The ICSI outcomes were evaluated prospectively. RESULTS: The clinical pregnancy and live birth rates were higher in DOR-COC score of I (15, 30.6%; 14, 38.9%) and NOR-COC score of I (19, 38.77%; 19, 52.7%) groups, compared with DOR-COC score of 0 (12, 24.4%; 3, 6.1%) and NOR-COC score of 0 (3, 6.1%; 0%) groups (p = 0.0001; 0.00002), respectively. Caspase-3 and cytochrome c expression levels were higher in DOR-COC score of 0 (23, 65.7%; 25, 71.4%) and NOR-COC score of 0 groups (19, 61.3%; 20, 64.5%), compared with DOR-COC score of I (8, 32%; 9, 36%) and NOR-COC score of I groups (7, 26.9%; 8, 30.8%) (p = 0.00297; p = 0.002), respectively. Lower expression levels of Hsp70 were found in DOR-COC score of 0 (11, 31.4%) and NOR-COC score of 0 groups (10, 32.3%), compared with DOR-COC score of I (16, 64%) and NOR-COC score of I groups (20, 76.9%) (p = 0.001), respectively. Hsp70 expression levels were positively correlated with the number of day 3 good-quality embryo and negatively correlated with estradiol levels in the DOR group. CONCLUSION: Our data suggest that COC score of 0 is associated with increased expression levels of apoptotic proteins, decreased expression levels of anti-apoptotic protein, and poor ICSI clinical outcomes in women with and without DOR.


Subject(s)
Infertility, Female , Ovarian Diseases , Ovarian Reserve , Apoptosis Regulatory Proteins , Caspase 3/genetics , Cytochromes c/metabolism , Female , Fertilization in Vitro , Granulosa Cells/metabolism , Humans , Infertility, Female/genetics , Infertility, Female/metabolism , Ovarian Diseases/metabolism , Ovarian Reserve/genetics , Pregnancy
2.
Eur J Obstet Gynecol Reprod Biol ; 268: 18-21, 2022 Jan.
Article in English | MEDLINE | ID: mdl-34794070

ABSTRACT

OBJECTIVE: The management of multiple pregnancies is still a challenge. The aim of this study was to compare the outcome of triplet pregnancies managed expectantly or by multifetal pregnancy reduction to twins. STUDY DESIGN: For this retrospective, comparative and monocentric study, the medical files of all women with triplets who admitted to our institution over a 13-year period were examined. Women requesting multifetal pregnancy reduction to have twins formed the study group, and women with triplets who wished to continue their pregnancies formed the control group. Main outcome measures were durations of pregnancies presented as number of weeks gestation, abortion rates, term and preterm birth rates, fetal loss and live birth rates. RESULTS: During the study period, 171 women with triplets admitted to our institution. One hundred fifty one patients are included in this study. Forty-five women carrying triplets wished to continue their pregnancies and 106 women requested multifetal pregnancy reduction to have twins. Fetal reduction of triplets to twins was associated with a significantly lower incidence of birth before 34th gestational week and higher incidence of late preterm and term birth rates without changing live birth rates. CONCLUSION: Multifetal pregnancy reduction of triplet pregnancies to twins resulted in a later gestational age at birth compared with the triplet gestations managed expectantly.


Subject(s)
Pregnancy, Triplet , Premature Birth , Birth Rate , Female , Gestational Age , Humans , Infant, Newborn , Pregnancy , Pregnancy Outcome/epidemiology , Pregnancy Reduction, Multifetal , Pregnancy, Multiple , Premature Birth/epidemiology , Retrospective Studies , Watchful Waiting
3.
Gynecol Endocrinol ; 36(8): 678-681, 2020 Aug.
Article in English | MEDLINE | ID: mdl-32129695

ABSTRACT

Betatrophin, which regulates glucose metabolism, is primarily expressed in liver and fat tissue. We aimed to investigate betatrophin levels in patients with polycystic ovary syndrome (PCOS) that is the most common endocrine pathology in women of reproductive age. A total of 69 women were included in this prospective study: 35 patients with PCOS (18 obese and 17 lean) and 34 healthy controls (17 obese and 17 lean). Patients who met the criteria were compared regarding betatrophin levels and other hormonal values. Serum betatrophin level did not differ between obese PCOS patients and obese controls, and lean PCOS patients and lean controls; while significantly increased in obese PCOS patients and controls compared to lean PCOS patients and controls. Total testosterone and androstenedione were significantly higher in patients with PCOS than in controls both in the obese and lean groups, while sex hormone-binding globulin was significantly lower in patients with PCOS than in controls both in the obese and lean groups. However, remaining hormone values were similar between groups. Betatrophin level was significantly increased in obese patients compared to lean patients independent to the presence of PCOS.


Subject(s)
Angiopoietin-like Proteins/blood , Obesity/blood , Peptide Hormones/blood , Polycystic Ovary Syndrome/blood , Thinness/blood , Adult , Angiopoietin-Like Protein 8 , Body Mass Index , Case-Control Studies , Female , Humans , Insulin Resistance/physiology , Obesity/complications , Polycystic Ovary Syndrome/complications , Thinness/complications , Young Adult
4.
Aust N Z J Obstet Gynaecol ; 58(5): 560-563, 2018 10.
Article in English | MEDLINE | ID: mdl-29359457

ABSTRACT

BACKGROUND AND AIMS: The aim of this study was to investigate the effectiveness of a levonorgestrel-releasing intrauterine device (LNG-IUS) in the symptomatic relief of pain in women with endometriosis and additionally, to assess the changes in women's life quality and serum cancer antigen (CA) 125 levels. MATERIALS AND METHODS: All women who had an LNG-IUS inserted for the treatment of dysmenorrhea, chronic pelvic pain or both for more than six months over a two-year period were included in the study. Each woman was asked to complete questionnaires of the Short Form-36 and visual analogue scales (VAS) in the first visit and the third, sixth, ninth and twelfth months after the LNG-IUS insertion. CA 125 levels were measured at each visit. RESULTS: Forty-five women were included in the study. At the end of 12 months, mean dysmenorrhoea VAS score decreased from 6.13 to 2.88, mean dsyspareunia VAS score from 6.04 to 2.61 and CA 125 level from 50.67 to 22.45. Endometriomas reduced in size in six women (mean size decreased from 31 to 20 mm) and disappeared in three. CONCLUSIONS: Several favourable outcomes were found following LNG-IUS insertion: (i) dyspareunia and dysmenorrhoea were clearly reduced; (ii) the size of endometriomas were decreased; (iii) CA 125 levels significantly decreased; (iv) a few women experienced the typical systemic adverse effects of progestogens; however, LNG-IUS-related adverse events were generally tolerable and the discontinuation rate was as low as 6.66% (3/45).


Subject(s)
Contraceptive Agents, Female/administration & dosage , Dysmenorrhea/drug therapy , Endometriosis/drug therapy , Intrauterine Devices, Medicated , Levonorgestrel/administration & dosage , Pelvic Pain/drug therapy , Adult , CA-125 Antigen/blood , Chronic Pain/drug therapy , Chronic Pain/etiology , Contraceptive Agents, Female/adverse effects , Cross-Sectional Studies , Dysmenorrhea/etiology , Dyspareunia/drug therapy , Dyspareunia/etiology , Endometriosis/complications , Female , Humans , Levonorgestrel/adverse effects , Membrane Proteins/blood , Middle Aged , Pain Measurement , Pelvic Pain/etiology , Prospective Studies , Quality of Life , Surveys and Questionnaires , Young Adult
5.
Arch Gynecol Obstet ; 297(4): 915-918, 2018 04.
Article in English | MEDLINE | ID: mdl-29362926

ABSTRACT

PURPOSE: The presence of echogenic amniotic fluid at term gestation on sonography is uncommon. The aim of our study was to investigate the incidence of echogenic amniotic fluid at term pregnancy, and to determine how often echogenic amniotic fluid was associated with meconium. METHODS: All singleton pregnant women at term who were admitted to our labor unit and who delivered within 24 h of the ultrasound scan were included in the study. For each woman, gestational age, maternal age, gravidity, parity, the character of the amniotic fluid on ultrasound at admission (clear or echogenic), birth weight, and the character of the amniotic fluid on artificial or spontaneous rupture of membranes or on cesarean section (clear/with vernix/meconium-stained) were recorded. RESULTS: When amniotic fluid was assessed on ultrasound, among 278 patients, 9 (3.2%) patients' amniotic fluid was echogenic. When the amniotic fluid was assessed at delivery, the rates of meconium-stained amniotic fluid in women with and without echogenic amniotic fluid were 44.44% (4/9) and 9.3% (25/269), respectively; the difference was statistically significant (p = 0.035). We found a sensitivity and specificity of 13.79 and 97.99%, and a positive and negative predictive value of 44.44 and 90.7%, respectively, for echogenic amniotic fluid seen on ultrasound in identifying meconium-stained amniotic fluid. CONCLUSIONS: The incidence of echogenic amniotic fluid at term gestation was found as 3.2 and 44.4% of cases of echogenic amniotic fluid was associated with meconium.


Subject(s)
Amniotic Fluid/diagnostic imaging , Labor, Obstetric , Meconium/diagnostic imaging , Ultrasonography , Birth Weight , Cesarean Section , Female , Gestational Age , Humans , Incidence , Infant, Newborn , Maternal Age , Parity , Pregnancy , Sensitivity and Specificity , Term Birth , Turkey/epidemiology
6.
J Ultrasound Med ; 36(5): 1015-1019, 2017 May.
Article in English | MEDLINE | ID: mdl-28258603

ABSTRACT

OBJECTIVES: The aim of this study was to assess the incidence of an aberrant right subclavian artery (ARSA) among an unselected population during second-trimester sonography and to review the importance of this conotruncal variant as a marker of Down syndrome. METHODS: The presence or absence of an ARSA was assessed in an unselected population of 1913 second-trimester fetuses. RESULTS: Among the 1913 patients, an ARSA was detected in 20 fetuses (1.04%), all with a normal karyotype. Thirteen of 20 fetuses had an isolated ARSA, and 7 of them were nonisolated. Associated abnormal sonographic findings were an intracardiac echogenic focus (n = 3), a choroid plexus cyst (n = 1), pyelectasis (n = 1) and tetralogy of Fallot (n = 2). One of the cases of tetralogy of Fallot was also associated with a persistent left superior vena cava, a persistent right umbilical vein, hydrocephalus, rhombencephalosynapsis, and unilateral renal agenesis. There were only 2 fetuses with Down syndrome in this group, and both of them had a normal origin of the right subclavian artery. CONCLUSIONS: In an unselected population, an ARSA may be seen less frequently than in a high-risk population and may not be related to Down syndrome. An isolated ARSA is not a sufficient indication for karyotype analysis; it can be managed with noninvasive prenatal testing rather than invasive testing.


Subject(s)
Aneurysm/complications , Aneurysm/diagnostic imaging , Cardiovascular Abnormalities/complications , Cardiovascular Abnormalities/diagnostic imaging , Down Syndrome/complications , Pregnancy Trimester, Second , Subclavian Artery/abnormalities , Ultrasonography, Prenatal/methods , Adolescent , Adult , Aneurysm/embryology , Cardiovascular Abnormalities/embryology , Female , Humans , Incidence , Middle Aged , Pregnancy , Retrospective Studies , Subclavian Artery/diagnostic imaging , Subclavian Artery/embryology , Turkey , Young Adult
7.
Eur J Obstet Gynecol Reprod Biol ; 210: 265-269, 2017 Mar.
Article in English | MEDLINE | ID: mdl-28081479

ABSTRACT

OBJECTIVE: Our aim was to analyze our five-year experience in the diagnosis and treatment of occult urinary incontinence in women with pelvic organ prolapse. STUDY DESIGN: The medical records of all patients who were admitted to the Division of Urogynecology of Istanbul Faculty of Medicine between January 2008 and December 2013; in total, 1600 patients were retrospectively evaluated. The study population included 287 patients who had prolapse beyond the hymen and underwent two consecutive urodynamic studies with and without prolapse reduction. Demographic data, medical records, physical examination, full urogynecologic examination, urodynamic investigations, treatment modality, the results of the treatment and King's Health Questionnaire scores before treatment and at one-year follow-up were recorded. RESULTS: Eighty-five of 287 patients (29.6%) were continent, 20 (23.5%) of whom had occult stress urinary incontinence during cystometry. Among these 20 patients, 17 underwent anti-incontinence surgery; 12 were satisfied with their surgery and had no postoperative urinary leakage. Twenty (23.5%) patients had overactive bladder symptoms during urodynamic studies after prolapse reduction. King's Health Questionnaire scores before and after the operation, showed that health status of 12 patients was better, 1 patient was unsatisfied after the treatment, 2 patients' scores did not change and 2 patients were lost to follow up. CONCLUSIONS: In conclusion, the prevalence of occult urinary incontinence was 23.5% when using urodynamics with prolapse reduction. 12 of the 17 patients diagnosed with occult urinary incontinence were satisfied with surgery and had no postoperative urinary leakage.


Subject(s)
Gynecologic Surgical Procedures/adverse effects , Pelvic Organ Prolapse/complications , Postoperative Complications/etiology , Urinary Incontinence/etiology , Adult , Aged , Aged, 80 and over , Female , Humans , Middle Aged , Pelvic Organ Prolapse/surgery , Postoperative Complications/surgery , Retrospective Studies , Urinary Incontinence/diagnosis , Urinary Incontinence/surgery
8.
Eur J Obstet Gynecol Reprod Biol ; 187: 30-4, 2015 Apr.
Article in English | MEDLINE | ID: mdl-25739053

ABSTRACT

OBJECTIVE: The aim of this study was to investigate the relationship of cathepsin B, relaxin and anti-Mullerian hormone (AMH) in follicular fluid (FF) with pregnancy rates in infertility patients. STUDY DESIGN: Seventy-nine infertile couples who underwent ICSI were included in the study. The FF levels of cathepsin B, relaxin and AMH were measured using ELISA kits. RESULTS: The FF cathepsin B levels were statistically higher in pregnant patients compared with non-pregnant patients (0.20±0.13 versus 0.13±0.03; P<0.001). There were statistically significant differences in the total number of oocytes (10.00±6.85 versus 5.96±3.94); the mean number of M2 oocytes (8.65±5.63 versus 4.58±3.36) between the pregnant and non-pregnant patients (P<0.05). There were no significant correlations between pregnancy rates and relaxin and AMH (P>0.05). The area under the curve of cathepsin B for prediction of pregnancy was 0.662 (p=0.024, 95% Confidence Interval 0.528-0.797). CONCLUSIONS: This study demonstrated that increased level of cathepsin B in FF significantly correlates with a better chance of clinical pregnancy. Further studies are needed to clarify the role of cathepsin B in the reproductive process of humans.


Subject(s)
Anti-Mullerian Hormone/analysis , Cathepsin B/analysis , Follicular Fluid/chemistry , Infertility/therapy , Relaxin/analysis , Sperm Injections, Intracytoplasmic , Adult , Embryo Transfer , Female , Humans , Oocytes/physiology , Ovulation Induction , Pregnancy , Treatment Outcome
SELECTION OF CITATIONS
SEARCH DETAIL
...